2021-11-18 General

Treatments This article talks about the good long-term results of AstraZeneca’s polyclonal antibody (brand name Evusheld). The article says it’s a two shot therapy like a vaccine, and given pre-exposure gives 83% protection over six months, sort of like a vaccine. Unlike a vaccine, however, it should work just as well in people who are… Continue reading 2021-11-18 General

2021-11-10 General

Treatments Okay, this preprint is wild — if I understand it correctly. My understanding is that the authors made a thing — a Therapeutic Interfering Particle or TIP — which looks just like SARS-CoV-2 except it has a vastly stripped-down genome, one that doesn’t have all the instructions needed to make the enzymes and proteins… Continue reading 2021-11-10 General

2021-11-05 General

Treatment Fantastic news! Pfizer has a pill which, if you take it in the first three days after symptoms appear, cuts hospitalization by NINETY F PERCENT!!! If taken within the first five days, it’s ~85% effective. The pill, called Paxlovid, is a protease inhibitor, which ought to be easy to make and have low side… Continue reading 2021-11-05 General

2021-11-04 General

Genetics This preprint talks about using virus-like particles to study viruses. It looks enough like SARS-CoV-2 that it can get into cells, but then it can’t replicate. Essentially, it’s shooting blanks. This study identified a specific gene variant (which comes from Neanderthals!) which gives a 2x risk of respiratory failure. About 60% of people of… Continue reading 2021-11-04 General

2021-11-03 General

Deaths/Demographics In addition to just “numbers of deaths”, you can also estimate “years of life lost” to describe how bad an epidemic is. For example, HIV had a huuuuge number of years of life lost because the people who died from it were unusually young. This article looked at years of life lost to COVID-19… Continue reading 2021-11-03 General

2021-10-28 General

Treatment This paper says that a single infusion of a new-to-me polyclonal antibody — sotrovimab — is 85% effective at preventing hospitalization when given early to high-risk COVID-19 patients. The FDA already gave an EUA to sotrovimab on 26 May; Canada gave interim approval on 30 July (and bought 10,000 doses on 4 October), so… Continue reading 2021-10-28 General